Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anetumab ravtansine multi-indication phase 1b study in mesothelin-expressing advanced solid tumors
NL-OMON48947Phase 1Active, not recruiting
- Sponsor
- Bayer
- Start
- Nov 2017
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label trial of anetumab ravtansine in Non-small cell lung cancer adenocarcinoma (NSCLC), triple-negative breast cancer (TNBC), gastric adenocarcinoma and 4 more (6 arms), sponsored by Bayer. Primary endpoints: Maximum tolerated dose, Objective response rate and 1 more. Started Nov 2017; status: active, not recruiting.
02
Drugs
anetumab ravtansine
03
Conditions
Non-small cell lung cancer adenocarcinoma (NSCLC)triple-negative breast cancer (TNBC)gastric adenocarcinomagastroesophageal junction adenocarcinomathymic carcinoma (TC)
Beyond the preview
Go deeper on NL-OMON48947.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON48947.